公开(公告)号：US20220117991A1

公开(公告)日：2022-04-21

申请号：US17051549

申请日：2019-04-12

Applicant: Helperby Therapeutics Limited

Inventor： Anthony Coates ,  Yanmin Hu

IPC: A61K31/7072 ,  A61K31/4178 ,  A61K31/55 ,  A61K31/665 ,  A61K31/545 ,  A61K31/431 ,  A61P31/04

Abstract: The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and an antimicrobial compound selected from nitrofurantoin, mecillinam, fosfomycin, cephalexin and faropenem, or a pharmaceutically acceptable derivative or prodrug thereof. These combinations are particularly useful for the treatment of microbial infections.

公开(公告)号：US10888575B2

公开(公告)日：2021-01-12

申请号：US16317512

申请日：2017-07-11

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony Coates ,  Yanmin Hu

IPC: A61K31/7072 ,  A61P31/04 ,  A61K31/407 ,  A61K38/12

Abstract: The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a carbapenem or a pharmaceutically acceptable derivative thereof, optionally with a polymyxin selected from polymyxin E and polymyxin or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.

公开(公告)号：US20240197767A1

公开(公告)日：2024-06-20

申请号：US17768669

申请日：2020-10-09

Applicant: Helperby Therapeutics Limited

Inventor： Professor Anthony Coates ,  Yanmin Hu

IPC: A61K31/7072 ,  A61K31/65 ,  A61P31/04

CPC classification number: A61K31/7072 ,  A61K31/65 ,  A61P31/04

Abstract: The present invention relates to a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a tetracycline antibiotic or a pharmaceutically acceptable derivative or prodrug thereof, for use in treating a microbial infection, particularly a bacterial infection such as a urinary tract infection.

公开(公告)号：US10736888B2

公开(公告)日：2020-08-11

申请号：US15770674

申请日：2016-10-20

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony Coates ,  Yanmin Hu

IPC: A61K9/00 ,  A61K31/4745 ,  A61P31/06 ,  A61P31/08 ,  A61K31/351 ,  A61K31/7036

Abstract: The invention provides a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof, mupirocin or a pharmaceutically acceptable derivative thereof and neomycin or a pharmaceutically acceptable derivative thereof. This triple combination is particularly useful for the treatment and/or prevention of microbial infections.

公开(公告)号：US20160030506A1

公开(公告)日：2016-02-04

申请号：US14772538

申请日：2014-03-20

Applicant: Yanmin HU ,  HELPERBY THERAPEUTICS LIMITED

Inventor： Yanmin HU ,  Anthony COATES

IPC: A61K38/12 ,  A61K31/7072

CPC classification number: A61K38/12 ,  A61K31/7072 ,  Y02A50/401 ,  Y02A50/404 ,  Y02A50/406 ,  Y02A50/469 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479 ,  Y02A50/481 ,  Y02A50/483 ,  A61K2300/00

Abstract: The present invention relates to the use of a combination of an anti-retroviral agent such as zidovudine and an anti-microbial agent for killing clinically latent microorganisms associated with microbial infections and to novel combinations comprising an anti-retroviral agent such as zidovudine and an anti-microbial agent for the treatment of microbial infections.

Abstract translation: 本发明涉及抗逆转录病毒药物如齐多夫定和抗微生物剂的组合用于杀死与微生物感染相关的临床潜在微生物的组合，以及包含抗逆转录病毒药物如齐多夫定和抗 - 微生物剂用于治疗微生物感染。

公开(公告)号：US20190321441A1

公开(公告)日：2019-10-24

申请号：US16405011

申请日：2019-05-07

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony COATES ,  Yanmin HU

IPC: A61K38/12 ,  A61K31/145 ,  A61K31/135 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/405 ,  A61K31/416 ,  A61K31/5415 ,  A61K31/428 ,  A61K31/05 ,  A61K31/382 ,  A61K31/616

Abstract: The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.

公开(公告)号：US10335454B2

公开(公告)日：2019-07-02

申请号：US15537007

申请日：2015-12-18

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony Coates ,  Yanmin Hu

IPC: A61K31/05 ,  A61K38/12 ,  A61K31/145 ,  A61K31/216 ,  A61K31/382 ,  A61K31/405 ,  A61K31/416 ,  A61K31/428 ,  A61K31/616 ,  A61K31/135 ,  A61K31/192 ,  A61K31/196 ,  A61K31/5415

Abstract: The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.

公开(公告)号：US20190111067A1

公开(公告)日：2019-04-18

申请号：US15537119

申请日：2015-12-18

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony COATES ,  Yanmin HU

IPC: A61K31/7036 ,  A61K31/05 ,  A61K31/12 ,  A61K31/4525 ,  A61P31/04 ,  A61K36/9068

Abstract: The present invention relates to the use of one or more compounds selected from the following: carvacrol, thymol, curcumin and piperidine, in combination with an aminoglycoside, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The present invention also relates to novel combinations comprising one or more compounds selected from the following: carvacrol, thymol, curcumin and piperidine, in combination with an aminoglycoside, for use in the treatment of microbial infections.

公开(公告)号：US20180311232A1

公开(公告)日：2018-11-01

申请号：US15770674

申请日：2016-10-20

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony Coates ,  Yanmin HU

IPC: A61K31/4745 ,  A61K9/00 ,  A61P31/06 ,  A61P31/08

CPC classification number: A61K31/4745 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0073 ,  A61K31/351 ,  A61K31/7036 ,  A61K2300/00 ,  A61P31/06 ,  A61P31/08 ,  Y02A50/401 ,  Y02A50/404 ,  Y02A50/406 ,  Y02A50/469 ,  Y02A50/475 ,  Y02A50/479 ,  Y02A50/481 ,  Y02A50/483

Abstract: The invention provides a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof, mupirocin or a pharmaceutically acceptable derivative thereof and neomycin or a pharmaceutically acceptable derivative thereof. This triple combination is particularly useful for the treatment and/or prevention of microbial infections.

公开(公告)号：US20230233559A1

公开(公告)日：2023-07-27

申请号：US17641257

申请日：2020-09-10

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Professor Anthony Coates ,  Yanmin Hu

IPC: A61K31/506 ,  A61K31/4725 ,  A61P31/04

CPC classification number: A61K31/506 ,  A61K31/4725 ,  A61P31/04

Abstract: The present invention relates to a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a fluoroquinolone antibiotic or a pharmaceutically acceptable derivative or prodrug thereof, for use in treating a microbial infection, particularly a bacterial infection such as a urinary tract infection.